AngioDynamics Inc (ANGO)
Official siteHEALTHCARE • MEDICAL INSTRUMENTS & SUPPLIES • NASDAQ
Market Cap: $499.19M
Last updated: Nov 17, 2026 at 11:05 AM ET
AngioDynamics Inc (ANGO) Financials: Revenue, Profit and Cash Flow
AngioDynamics reported revenue of $320.17M for the fiscal year ended May 31, 2026, up 9.5% from the year before. That year, net income was -$36.74M with a net margin of -11.5%, operating cash flow was $3.09M and free cash flow was $508.00K. The quarter ended Aug 31, 2026 had revenue of $80.92M and net income of -$7.10M.
Revenue and Margins
The operating margin was -12.5% in the fiscal year ended May 2026. Over the 9 years to May 2026, revenue grew from $269.79M, a compound annual rate of 1.9%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| May 2026 | $320.17M | +9.5% | 54.6% | -12.5% | -11.5% |
| May 2025 | $292.50M | -3.8% | 53.9% | -13.7% | -11.6% |
| May 2024 | $303.91M | -10.3% | 50.9% | -63.3% | -60.7% |
| May 2023 | $338.75M | +7.1% | 51.4% | -15.1% | -15.5% |
| May 2022 | $316.22M | +8.7% | 52.4% | -9.0% | -8.4% |
| May 2021 | $291.01M | +10.2% | 53.9% | -12.1% | -10.8% |
| May 2020 | $264.16M | -2.4% | 56.9% | -63.3% | -63.1% |
| May 2019 | $270.63M | +3.4% | 57.6% | -3.5% | 22.7% |
| May 2018 | $261.65M | -3.0% | 55.0% | -5.4% | 6.2% |
| May 2017 | $269.79M | N/A | 53.4% | -4.1% | 1.9% |
Income Statement
In the fiscal year ended May 2026, the net loss widened from the year before. In the quarter ended Aug 2026, the net loss narrowed from the same quarter a year earlier.
Annual
| Line item | May 2026 | May 2025 | May 2024 | May 2023 | May 2022 | May 2021 | May 2020 | May 2019 | May 2018 | May 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $320.17M | $292.50M | $303.91M | $338.75M | $316.22M | $291.01M | $264.16M | $270.63M | $261.65M | $269.79M |
| Cost of revenue | $145.28M | $134.79M | $149.22M | $164.51M | $150.49M | $134.22M | $113.89M | $114.63M | $117.80M | $125.84M |
| Gross profit | $174.89M | $157.71M | $154.70M | $174.25M | $165.73M | $156.79M | $150.27M | $156.00M | $143.86M | $143.95M |
| Research and development | $29.45M | $26.22M | $31.51M | $29.88M | $30.74M | $36.39M | $29.68M | $28.26M | $24.34M | $24.15M |
| Operating income | -$39.93M | -$39.95M | -$192.44M | -$51.18M | -$28.47M | -$35.28M | -$167.10M | -$9.40M | -$14.17M | -$11.18M |
| Net income | -$36.74M | -$33.99M | -$184.35M | -$52.44M | -$26.55M | -$31.55M | -$166.79M | $61.34M | $16.34M | $5.01M |
| EBITDA | -$13.05M | -$9.21M | -$165.54M | -$20.86M | $88.00K | -$9.28M | -$143.42M | $16.28M | $8.96M | $13.36M |
Quarterly
| Line item | Aug 2026 | May 2026 | Feb 2026 | Nov 2025 | Aug 2025 | May 2025 | Feb 2025 | Nov 2024 | Aug 2024 | May 2024 | Feb 2024 | Nov 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $80.92M | $86.61M | $78.42M | $79.43M | $75.71M | $80.16M | $72.00M | $72.84M | $67.49M | $70.98M | $75.18M | $79.07M |
| Gross profit | $48.04M | $46.77M | $41.48M | $44.78M | $41.86M | $42.22M | $38.86M | $39.91M | $36.72M | $38.52M | $35.86M | $40.26M |
| Operating income | -$7.30M | -$10.20M | -$12.95M | -$6.13M | -$10.66M | -$5.79M | -$9.97M | -$11.09M | -$13.10M | -$14.45M | -$199.90M | -$13.12M |
| Net income | -$7.10M | -$11.40M | -$8.08M | -$6.35M | -$10.90M | -$6.05M | -$4.41M | -$10.74M | -$12.80M | -$13.45M | -$187.74M | -$29.05M |
Balance Sheet
As of May 2026, cash and equivalents of $53.86M were 20.2% of total assets of $267.16M, against total liabilities of $96.34M.
Annual
| Line item | May 2026 | May 2025 | May 2024 | May 2023 | May 2022 | May 2021 | May 2020 | May 2019 | May 2018 | May 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $267.16M | $280.14M | $317.67M | $532.64M | $552.75M | $561.44M | $594.21M | $836.44M | $705.47M | $707.96M |
| Current assets | $163.39M | $168.32M | $193.25M | $163.54M | $143.34M | $140.88M | $152.91M | $315.29M | $168.03M | $153.91M |
| Cash and equivalents | $53.86M | $55.89M | $76.06M | $44.62M | $28.82M | $48.16M | $54.44M | $227.64M | $74.10M | $47.54M |
| Total liabilities | $96.34M | $97.17M | $112.08M | $154.34M | $128.26M | $121.98M | $139.34M | $221.62M | $162.88M | $192.93M |
| Short-term debt | N/A | $2.24M | $4.73M | $14.76M | $8.78M | $0 | $836.00K | $12.13M | $7.10M | $14.63M |
| Long-term debt | N/A | N/A | N/A | $49.82M | $25.00M | $20.00M | $40.00M | $124.41M | $86.62M | $91.32M |
| Shareholder equity | $170.82M | $182.97M | $205.59M | $378.30M | $424.49M | $439.46M | $454.87M | $614.82M | $542.60M | $515.03M |
Quarterly
| Line item | Aug 2026 | May 2026 | Feb 2026 | Nov 2025 | Aug 2025 | May 2025 | Feb 2025 | Nov 2024 | Aug 2024 | May 2024 | Feb 2024 | Nov 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $241.93M | $267.16M | $260.68M | $269.68M | $265.64M | $280.14M | $285.42M | $291.55M | $293.63M | $317.67M | $324.84M | $499.62M |
| Total liabilities | $77.97M | $96.34M | $87.32M | $93.35M | $86.79M | $97.17M | $99.55M | $104.78M | $97.05M | $112.08M | $106.14M | $98.40M |
| Cash and equivalents | $33.97M | $53.86M | $37.81M | $41.64M | $38.76M | $55.89M | $44.76M | $54.09M | $55.01M | $76.06M | $78.45M | $60.90M |
| Shareholder equity | $163.96M | $170.82M | $173.36M | $176.33M | $178.85M | $182.97M | $185.87M | $186.77M | $196.58M | $205.59M | $218.70M | $401.23M |
Cash Flow
In the fiscal year ended May 2026, free cash flow was 16.4% of operating cash flow.
Annual
| Line item | May 2026 | May 2025 | May 2024 | May 2023 | May 2022 | May 2021 | May 2020 | May 2019 | May 2018 | May 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $3.09M | -$10.13M | -$28.16M | $78.00K | -$7.19M | $24.09M | -$14.55M | $37.44M | $41.29M | $55.74M |
| Capital expenditures | $2.58M | $4.46M | $2.52M | $3.81M | $4.30M | $5.19M | $7.24M | $3.12M | $2.39M | $3.00M |
| Free cash flow | $508.00K | -$14.59M | -$30.68M | -$3.73M | -$11.49M | $18.91M | -$21.79M | $34.32M | $38.90M | $52.74M |
| Share repurchases | $0 | $1.67M | $0 | $0 | N/A | N/A | N/A | N/A | N/A | $13.56M |
| Investing cash flow | -$5.95M | -$10.18M | $123.72M | -$9.75M | -$19.31M | -$13.71M | -$63.34M | $82.55M | -$3.66M | -$2.55M |
| Financing cash flow | $564.00K | -$255.00K | -$64.25M | $25.42M | $7.68M | -$16.99M | -$95.24M | $33.93M | -$11.55M | -$37.98M |
Quarterly
| Line item | Aug 2026 | May 2026 | Feb 2026 | Nov 2025 | Aug 2025 | May 2025 | Feb 2025 | Nov 2024 | Aug 2024 | May 2024 | Feb 2024 | Nov 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$15.33M | $17.45M | -$3.11M | $4.66M | -$15.91M | $18.81M | -$13.16M | $2.47M | -$18.25M | $5.00M | -$12.53M | $5.27M |
| Capital expenditures | $3.15M | $2.10M | $1.51M | $1.62M | $1.55M | $3.09M | $3.19M | $1.96M | $2.40M | $2.68M | $1.85M | $1.79M |
| Free cash flow | -$18.48M | $15.35M | -$4.62M | $3.04M | -$17.46M | $15.72M | -$16.35M | $512.00K | -$20.66M | $2.32M | -$14.37M | $3.47M |
Frequently Asked Questions About ANGO
What is AngioDynamics' annual revenue?
AngioDynamics reported revenue of $320.17M for the fiscal year ended May 31, 2026.
How fast is AngioDynamics' revenue growing?
Revenue was up 9.5% for the fiscal year ended May 31, 2026 compared with the year before. The compound annual revenue growth rate over 3 years was -1.9%.
Is AngioDynamics profitable?
No. AngioDynamics reported net income of -$36.74M for the fiscal year ended May 31, 2026, with a net margin of -11.5%.
How much free cash flow does ANGO generate?
For the fiscal year ended May 31, 2026, operating cash flow of $3.09M minus capital expenditures of $2.58M produced free cash flow of $508.00K.
How much debt does AngioDynamics have?
The balance sheet dated May 31, 2026 reported cash and equivalents of $53.86M.
ANGO pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts